Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation

BACKGROUND: Oral dabigatran was recently approved as an alternative to warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran has a fixed dosage and few drug interactions, and does not require anticoagulation monitoring o...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jiyoon C, DiBonaventura, Marco d, Kopenhafer, Lewis, Nelson, Winnie W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923612/
https://www.ncbi.nlm.nih.gov/pubmed/24532967
http://dx.doi.org/10.2147/PPA.S56187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923612/
https://www.ncbi.nlm.nih.gov/pubmed/24532967
http://dx.doi.org/10.2147/PPA.S56187

Ejemplares similares